These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30386613)

  • 1. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
    Takaya H; Kawaratani H; Tsuji Y; Nakanishi K; Saikawa S; Sato S; Sawada Y; Kaji K; Okura Y; Shimozato N; Kitade M; Akahane T; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
    United European Gastroenterol J; 2018 Nov; 6(9):1401-1409. PubMed ID: 30386613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
    Takaya H; Namisaki T; Moriya K; Shimozato N; Kaji K; Ogawa H; Ishida K; Tsuji Y; Kaya D; Takagi H; Fujinaga Y; Nishimura N; Sawada Y; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
    World J Gastroenterol; 2020 Dec; 26(45):7232-7241. PubMed ID: 33362379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
    Takaya H; Namisaki T; Shimozato N; Kaji K; Kitade M; Moriya K; Sato S; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
    World J Gastrointest Oncol; 2019 May; 11(5):424-435. PubMed ID: 31139312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of von Willebrand Factor Antigen in Predicting Survival of Patients with HBV-Related Cirrhosis.
    Pan Y; Guo R; Lv Y; Cui D; Xie J
    Can J Gastroenterol Hepatol; 2022; 2022():9035971. PubMed ID: 35360443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C.
    Maieron A; Salzl P; Peck-Radosavljevic M; Trauner M; Hametner S; Schöfl R; Ferenci P; Ferlitsch M
    Aliment Pharmacol Ther; 2014 Feb; 39(3):331-8. PubMed ID: 24308724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study.
    Liu Y; Wang X; Li S; Hu H; Zhang D; Hu P; Yang Y; Ren H
    J Proteomics; 2014 Jun; 106():99-112. PubMed ID: 24769235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.
    Schwarz C; Fitschek F; Mittlböck M; Saukel V; Bota S; Ferlitsch M; Ferlitsch A; Bodingbauer M; Kaczirek K
    Gut Liver; 2020 Mar; 14(2):218-224. PubMed ID: 30428508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
    Enomoto M; Takaya H; Namisaki T; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Inoue T; Matsumoto M; Yoshiji H
    Hepatol Res; 2022 Apr; 52(4):390-400. PubMed ID: 34964539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.
    Kalambokis GN; Oikonomou A; Christou L; Kolaitis NI; Tsianos EV; Christodoulou D; Baltayiannis G
    J Hepatol; 2016 Nov; 65(5):921-928. PubMed ID: 27297911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent property of intra-platelet VWF in liver regeneration and HCC recurrence: A prospective multicenter study.
    Aryal B; Yamakuchi M; Shimizu T; Kadono J; Furoi A; Gejima K; Takenouchi K; Komokata T; Hashiguchi T; Imoto Y
    Cancer Biomark; 2019; 26(1):51-61. PubMed ID: 31322547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.
    Gatselis NK; Tornai T; Shums Z; Zachou K; Saitis A; Gabeta S; Albesa R; Norman GL; Papp M; Dalekos GN
    World J Gastroenterol; 2020 Sep; 26(34):5130-5145. PubMed ID: 32982114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
    Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
    Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models.
    Ho SY; Wang LC; Hsu CY; Liu PH; Hsia CY; Huang YH; Huo TI
    J Gastrointest Surg; 2020 Aug; 24(8):1860-1862. PubMed ID: 32424685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.
    Györi GP; Pereyra D; Rumpf B; Hackl H; Köditz C; Ortmayr G; Reiberger T; Trauner M; Berlakovich GA; Starlinger P
    Hepatology; 2020 Aug; 72(2):584-594. PubMed ID: 31773739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.
    Rutter K; Etschmaier A; Ferlitsch M; Maieron A; Hametner S; Horvatits T; Paternostro R; Salzl P; Reiberger T; Peck-Radosavljevic M; Quehenberger P; Hofer H; Trauner M; Ferenci P; Ferlitsch A
    Dig Liver Dis; 2016 Oct; 48(10):1194-9. PubMed ID: 27476467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.
    Starlinger P; Pereyra D; Haegele S; Braeuer P; Oehlberger L; Primavesi F; Kohler A; Offensperger F; Reiberger T; Ferlitsch A; Messner B; Beldi G; Staettner S; Brostjan C; Gruenberger T
    Hepatology; 2018 Apr; 67(4):1516-1530. PubMed ID: 29140542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.